Report any blurring, difficulty reading, or changes in colour perception to a healthcare professional immediately. An ophthalmologic assessment is essential, as early detection of chloroquine-related retinopathy can prevent permanent vision loss.
Chloroquine can interact with certain beta-blockers and calcium-channel blockers by affecting heart rhythm. It's important to inform your prescriber about all cardiovascular drugs you are using so they can assess the need for ECG monitoring.
Chloroquine is classified as Category B2 in pregnancy, meaning animal studies have not shown risk but human data are limited. It may be used when the benefit outweighs potential risks, but alternatives such as mefloquine or atovaquone-proguanil are often preferred. Discuss travel plans with your obstetrician.
Arilen tablets are imprinted with distinct codes: the 250 mg tablets carry the “A-250” imprint, while the 500 mg tablets display “A-500”. Check the packaging or consult your pharmacist if you are uncertain.
Chloroquine can cause hypoglycaemia by increasing insulin sensitivity. If you have diabetes, monitor your blood glucose closely, especially when starting or adjusting the dose, and inform your diabetes care team.
Calcium does not have a known direct interaction with chloroquine. However, taking any supplement with a large amount of minerals may interfere with drug absorption if taken simultaneously. Space the supplement at least two hours apart from the Arilen dose.
Because chloroquine can prolong the QT interval, a baseline ECG helps identify any pre-existing prolongation. This information guides safe dosing and informs the need for periodic cardiac monitoring.
Yes, chloroquine phosphate is available as a generic medication marketed under various brand names. The active ingredient, dosage forms, and strengths are identical; only the packaging and manufacturer differ.
Expired tablets should not be taken. Return them to a pharmacy participating in the NHS Drug Disposal Programme or follow local waste-management guidelines for hazardous medicines.
Yes, but keep the medication in its original labelled container, carry a copy of the prescription or a doctor’s note, and be prepared to declare it at customs if requested. This helps avoid confusion with security personnel.
Aralen is a brand-name medication that contains chloroquine phosphate as its sole active ingredient. It is supplied as oral pills in strengths of 250 mg and 500 mg. In the United Kingdom, chloroquine phosphate is classified as an antiparasitic agent and is authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment and prophylaxis of malaria. It is also used in certain autoimmune conditions, but it has no approved indication for COVID-19 in the UK.
Chloroquine belongs to a class of drugs known as 4-aminoquinolines. After oral ingestion, the drug is absorbed from the gastrointestinal tract and distributes widely throughout body tissues, including the liver, spleen, lungs, and melanin-rich structures such as the eye.
The drug’s onset of action for malaria is typically within a few hours, with peak plasma concentrations reached about 2-4 hours after a dose. Its elimination half-life ranges from 1 to 2 weeks because of extensive tissue binding, which underlies its weekly dosing schedule for malaria prophylaxis.
COVID-19: Chloroquine was investigated early in the pandemic as a potential antiviral agent, but the MHRA has not approved Arilen for the treatment or prevention of COVID-19. Current clinical guidelines advise against its routine use for this indication.
Chloroquine is sometimes prescribed off-label for rheumatoid arthritis and systemic lupus erythematosus. Small-scale studies and long-term clinical experience suggest modest reductions in disease activity and joint pain. Use for these conditions must be supervised by a rheumatologist, with regular monitoring for retinal toxicity and cardiac effects.
Early in-vitro studies indicated that chloroquine could inhibit SARS-CoV-2 replication, leading to widespread interest. However, subsequent randomized controlled trials (RCTs) have not demonstrated a clinically meaningful benefit, and the MHRA has issued safety warnings about cardiotoxicity at doses explored for COVID-19. Off-label use for COVID-19 is not recommended outside of a controlled clinical trial setting.
All off-label applications require individualized risk assessment and close medical supervision.
Any of the following require immediate medical attention: visual changes (blurred vision, difficulty reading), palpitations, fainting, severe abdominal pain, or signs of allergic reaction such as swelling of the face or throat.
Patients should disclose all current medications, supplements, and herbal products to their prescriber before initiating Arilen.
This regimen delivers the conventional 600 mg base loading dose followed by 300 mg base maintenance doses, matching established malaria treatment protocols.
This article provides educational information about Arilen and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
